2014

Reddi HV, Jenkins S, Theis J, Thomas BC, Connors LH, Van Rhee F, Highsmith WE.  Homozygosity for the V122I mutation in transthyretin is associated with earlier onset of cardiac amyloidosis in the African American population in the seventh decade of life.  J Mol Diagn, 16(1):68-74, 2014.  View in: PubMed

Mahmood S, Palladini G, Sanchorawala V, Wechalekar A.  Update on treatment of light chain amyloidosis.  Haematologica, (2):209-21, 2014.  View in: PubMed

Merlini G, Comenzo RL, Seldin DC, Wechalekar A, Gertz MA.  Immunoglobulin light chain amyloidosis.  Expert Rev Hematol, 7(1):143-56, 2014.  View in: PubMed

Gray Gilstrap L, Niehaus E, Malhotra R, Ton VK, Watts J, Seldin DC, Madsen JC, Semigran MJ.  Predictors of survival to orthotopic heart transplant in patients with light chain amyloidosis.  J Heart Lung Transplant, 33(2):149-56, 2014.  View in: PubMed

Girnius S, Seldin DC, Meier-Ewert HK, Sloan JM, Quillen K, Ruberg FL, Berk JL, Doros G, Sanchorawala V.  Safety and efficacy of high-dose melphalan and auto-SCT in patients with AL amyloidosis and cardiac involvement.  Bone Marrow Transplant, 49(3):434-9, 2014.  View in: PubMed

Phay M, Blinder V, Macy S, Greene MJ, Wooliver DC, Liu W, Planas A, Walsh DM, Connors LH, Primmer SR, Planque SA, Paul S, O’Nuallain B.  Transthyretin aggregate-specific antibodies recognize cryptic epitopes on patient-derived amyloid fibrils.  Rejuvenation Res, 17(2):97-104, 2014.  View in: PubMed

von Keudell G, Sanchorawala V, O”Hara C, C Seldin D, Sloan JM.  Simultaneous presentation of kappa-restricted chronic lymphocytic leukemia and lambda light chain AL amyloidosis.  Amyloid: J Prot Folding Disorders, 21(2):124-7, 2014.  View in: PubMed

Lichtman EI, Seldin DC, Shelton A, Sanchorawala V.  Single agent lenalidomide three times a week induces hematologic responses in AL amyloidosis patients on dialysis.  Am J Hematol, 89(7):706-8, 2014.  View in: PubMed

Lee SY, Sanchorawala V, Seldin DC, Mark Sloan J, Andrea N, Quillen K.  Plerixafor-augmented peripheral blood stem cell mobilization in AL amyloidosis with cardiac involvement: a case series.  Amyloid: J Prot Folding Disorders, 21(3):149-53, 2014.  View in: PubMed

Ruzhansky K, Scoon J, Weimer LH, Maurer MS, Berk JL, Brannagan TH.  Discordant phenotype in monozygotic female twins with Lys35Thr TTR familial amyloidotic polyneuropathy.  J Clin Neuromuscul Dis, 16(1):1-6, 2014.  View in: PubMed

Suanprasert N, Berk JL, Benson MD, Dyck PJ, Klein CJ, Gollob JA, Bettencourt BR, Karsten V, Dyck PJ.  Retrospective study of a TTR FAP cohort to modify NIS+7 for therapeutic trials.  J Neurol Sci, 344(1-2):121-8, 2014.  View in: PubMed

Guan J, Mishra S, Qiu Y, Shi J, Trudeau K, Las G, Liesa M, Shirihai OS, Connors LH, Seldin DC, Falk RH, MacRae CA, Liao R.  Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity.  EMBO Mol Med, 6(11):1493-507, 2014.  View in: PubMed

Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Bladé J, Fermand JP, Hassoun H, Heffner L, Kukreti V, Vescio RA, Pei L, Enny C, Esseltine DL, van de Velde H, Cakana A, Comenzo RL.  Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis.  Blood, 24(16):2498-506, 2014.  View in: PubMed

Freeman B, Brauneis D, Seldin DC, Quillen K, Sloan JM, Renteria AS, Shelton AC, Teschner T, Finn KT, Sanchorawala V.  Hospital admissions following outpatient administration of high-dose melphalan and autologous SCT for AL amyloidosis.  Bone Marrow Transplant, 49(10):1345-6, 2014.  View in: PubMed

Sanchorawala V.  High dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis.  Hematol Oncol Clin North Am, 28(6):1131-44, 2014.  View in: PubMed

Fu J, Seldin DC, Berk JL, Sun F, O”Hara C, Cui H, Sanchorawala V.  Lymphadenopathy as a manifestation of amyloidosis: a case series.   Amyloid: J Prot Folding Disorders, 21(4):256-60, 2014.  View in: PubMed